Skip to main content
. 2023 Jun 16;14:1190883. doi: 10.3389/fimmu.2023.1190883

Figure 3.

Figure 3

There are many detours and challenges in the CTA-based digestive tract tumor immunotherapy. New strategies and cutting-edge technology provided opportunities to overcome these difficulties.